Abstract

Dyskeratosis congenita (DC) is a rare genetic disorder characterized by deficiencies in telomere maintenance leading to very short telomeres and the premature onset of certain age-related diseases, including pulmonary fibrosis (PF). PF is thought to derive from epithelial failure, particularly that of type II alveolar epithelial (AT2) cells, which are highly dependent on Wnt signaling during development and adult regeneration. We use human iPSC-derived AT2 (iAT2) cells to model how short telomeres affect AT2 cells. Cultured DC mutant iAT2 cells accumulate shortened, uncapped telomeres and manifest defects in the growth of alveolospheres, hallmarks of senescence, and apparent defects in Wnt signaling. The GSK3 inhibitor, CHIR99021, which mimics the output of canonical Wnt signaling, enhances telomerase activity and rescues the defects. These findings support further investigation of Wnt agonists as potential therapies for DC related pathologies.

Data availability

Sequencing data was deposited in GEO: GSE160871

The following data sets were generated

Article and author information

Author details

  1. Rafael Jesus Fernandez III

    Medical Scientist Training Program, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9295-4810
  2. Zachary J G Gardner

    Medical Scientist Training Program, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  3. Katherine J Slovik

    Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  4. Derek C Liberti

    Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2991-9283
  5. Katrina N Estep

    Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  6. Wenli Yang

    Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  7. Qijun Chen

    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  8. Garrett T Santini

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  9. Javier V Perez

    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  10. Sarah Root

    College of Arts and Sciences and Vagelos Scholars Program, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  11. Ranvir Bhatia

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  12. John W Tobias

    Penn Genomic Analysis Core, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  13. Apoorva Babu

    Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  14. Michael P Morley

    Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  15. David B Frank

    Penn-CHOP Lung Biology Institute, Children's Hospital of Philadelphia, Philadelphia, United States
    Competing interests
    No competing interests declared.
  16. Edward E Morrisey

    Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    Edward E Morrisey, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5785-1939
  17. Christopher J Lengner

    Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, United States
    For correspondence
    lengner@vet.upenn.edu
    Competing interests
    No competing interests declared.
  18. F Brad Johnson

    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States
    For correspondence
    johnsonb@pennmedicine.upenn.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7443-7227

Funding

National Institute on Aging (R21AG054209)

  • Christopher J Lengner
  • F Brad Johnson

National Institute on Aging (5T32AG000255)

  • Rafael Jesus Fernandez III

Team Telomere/Penn Orphan Disease Center

  • Christopher J Lengner
  • F Brad Johnson

National Heart, Lung, and Blood Institute (R01HL148821)

  • Christopher J Lengner
  • F Brad Johnson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Fernandez et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,651
    views
  • 341
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rafael Jesus Fernandez III
  2. Zachary J G Gardner
  3. Katherine J Slovik
  4. Derek C Liberti
  5. Katrina N Estep
  6. Wenli Yang
  7. Qijun Chen
  8. Garrett T Santini
  9. Javier V Perez
  10. Sarah Root
  11. Ranvir Bhatia
  12. John W Tobias
  13. Apoorva Babu
  14. Michael P Morley
  15. David B Frank
  16. Edward E Morrisey
  17. Christopher J Lengner
  18. F Brad Johnson
(2022)
GSK3 inhibition rescues growth and telomere dysfunction in dyskeratosis congenita iPSC-derived type II alveolar epithelial cells
eLife 11:e64430.
https://doi.org/10.7554/eLife.64430

Share this article

https://doi.org/10.7554/eLife.64430

Further reading

    1. Stem Cells and Regenerative Medicine
    Mami Matsuo-Takasaki, Sho Kambayashi ... Yohei Hayashi
    Tools and Resources

    Human induced pluripotent stem cells (hiPSCs) are promising resources for producing various types of tissues in regenerative medicine; however, the improvement in a scalable culture system that can precisely control the cellular status of hiPSCs is needed. Utilizing suspension culture without microcarriers or special materials allows for massive production, automation, cost-effectiveness, and safety assurance in industrialized regenerative medicine. Here, we found that hiPSCs cultured in suspension conditions with continuous agitation without microcarriers or extracellular matrix components were more prone to spontaneous differentiation than those cultured in conventional adherent conditions. Adding PKCβ and Wnt signaling pathway inhibitors in the suspension conditions suppressed the spontaneous differentiation of hiPSCs into ectoderm and mesendoderm, respectively. In these conditions, we successfully completed the culture processes of hiPSCs, including the generation of hiPSCs from peripheral blood mononuclear cells with the expansion of bulk population and single-cell sorted clones, long-term culture with robust self-renewal characteristics, single-cell cloning, direct cryopreservation from suspension culture and their successful recovery, and efficient mass production of a clinical-grade hiPSC line. Our results demonstrate that precise control of the cellular status in suspension culture conditions paves the way for their stable and automated clinical application.

    1. Stem Cells and Regenerative Medicine
    Wenxin Ma, Lian Zhao ... Wei Li
    Research Article

    Microglia exhibit both maladaptive and adaptive roles in the pathogenesis of neurodegenerative diseases and have emerged as a cellular target for central nervous system (CNS) disorders, including those affecting the retina. Replacing maladaptive microglia, such as those impacted by aging or over-activation, with exogenous microglia that can enable adaptive functions has been proposed as a potential therapeutic strategy for neurodegenerative diseases. To investigate microglia replacement as an approach for retinal diseases, we first employed a protocol to efficiently generate human-induced pluripotent stem cell (hiPSC)-derived microglia in quantities sufficient for in vivo transplantation. These cells demonstrated expression of microglia-enriched genes and showed typical microglial functions such as LPS-induced responses and phagocytosis. We then performed xenotransplantation of these hiPSC-derived microglia into the subretinal space of adult mice whose endogenous retinal microglia have been pharmacologically depleted. Long-term analysis post-transplantation demonstrated that transplanted hiPSC-derived microglia successfully integrated into the neuroretina as ramified cells, occupying positions previously filled by the endogenous microglia and expressed microglia homeostatic markers such as P2ry12 and Tmem119. Furthermore, these cells were found juxtaposed alongside residual endogenous murine microglia for up to 8 months in the retina, indicating their ability to establish a stable homeostatic state in vivo. Following retinal pigment epithelial cell injury, transplanted microglia demonstrated responses typical of endogenous microglia, including migration, proliferation, and phagocytosis. Our findings indicate the feasibility of microglial transplantation and integration in the retina and suggest that modulating microglia through replacement may be a therapeutic strategy for treating neurodegenerative retinal diseases.